SWS Medical(SH:688410) Ge Long Hui A P P·2026-01-30 07:45Core Viewpoint - The company, Shanwaishan (688410.SH), expects a significant increase in net profit for the year 2025, driven by its leading position in the domestic blood purification equipment market and improved sales of self-produced consumables [1] Financial Performance - The projected net profit attributable to the parent company is estimated to be between 140 million to 159 million yuan, representing an increase of 69.4686 million to 88.6079 million yuan compared to the previous year, which is a year-on-year increase of 98% to 125% [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses is expected to be between 134 million to 154 million yuan, with an increase of 77.1902 million to 97.2024 million yuan compared to the previous year, indicating a year-on-year increase of 135% to 170% [1] Business Drivers - The main reasons for the performance change include: 1. The company’s leading technological advantage and strong brand effect have led to an increase in market share, driving steady growth in sales revenue of blood purification equipment [1] 2. Significant growth in sales revenue from self-produced blood purification consumables during the reporting period [1] 3. Increased production and sales volume have led to a decrease in unit fixed costs for self-produced consumables, resulting in improved gross margins and overall profitability [1]